FDA Approved: HYZAAR — Supplemental Application (Organon LLC)

View source ↗

Summary

The FDA approved a supplemental application for HYZAAR, a fixed-dose combination of losartan potassium and hydrochlorothiazide, submitted by Organon LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Hyzaar (losartan/hydrochlorothiazide)

Snippet

SUPPL AP for HYZAAR (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)